Live Attenuated Reassortant Vaccines Based on A/Leningrad/134/17/57 Master Donor Virus Against H5 Avian Influenza.

Q3 Immunology and Microbiology

Open Microbiology Journal Pub Date : 2017-11-30 eCollection Date: 2017-01-01 DOI:10.2174/1874285801711010316

Irina Kiseleva, Natalie Larionova, Larisa Rudenko

{"title":"Live Attenuated Reassortant Vaccines Based on A/Leningrad/134/17/57 Master Donor Virus Against H5 Avian Influenza.","authors":"Irina Kiseleva, Natalie Larionova, Larisa Rudenko","doi":"10.2174/1874285801711010316","DOIUrl":null,"url":null,"abstract":"Background: The H5N1 avian influenza was first recognized in humans in Hong Kong 20 years ago. Current enzootic spread of highly pathogenic H5N1 virus among wild and domestic poultry and a number of severe human respiratory diseases caused by this pathogen have stimulated necessity of development of potentially pandemic influenza vaccines.Discussion: In the past few years, significant research was conducted on how to prevent H5N1 influenza. Live, attenuated cold-adapted reassortant influenza vaccine (LAIV) is considered as one of the most promising candidates for pandemic and prepandemic vaccines. LAIV has proven to be safe and efficacious; pandemic LAIV might be more effective than inactivated vaccine in providing broader immune response.Conclusion: This review covers development of LAIVs against potential avian \"pandemic\" H5N1 subtype based on cold-adapted A/Leningrad/134/17/57 (H2N2) master donor virus backbone, and their preclinical and clinical studies.","PeriodicalId":38953,"journal":{"name":"Open Microbiology Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5737031/pdf/","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Microbiology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874285801711010316","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Immunology and Microbiology","Score":null,"Total":0}

引用次数: 4

Abstract

Background: The H5N1 avian influenza was first recognized in humans in Hong Kong 20 years ago. Current enzootic spread of highly pathogenic H5N1 virus among wild and domestic poultry and a number of severe human respiratory diseases caused by this pathogen have stimulated necessity of development of potentially pandemic influenza vaccines.

Discussion: In the past few years, significant research was conducted on how to prevent H5N1 influenza. Live, attenuated cold-adapted reassortant influenza vaccine (LAIV) is considered as one of the most promising candidates for pandemic and prepandemic vaccines. LAIV has proven to be safe and efficacious; pandemic LAIV might be more effective than inactivated vaccine in providing broader immune response.

Conclusion: This review covers development of LAIVs against potential avian "pandemic" H5N1 subtype based on cold-adapted A/Leningrad/134/17/57 (H2N2) master donor virus backbone, and their preclinical and clinical studies.

Abstract Image

查看原文本刊更多论文

基于A/Leningrad/134/17/57主供体病毒的H5禽流感减毒重组活疫苗研究

背景:20年前香港首次发现人类感染H5N1禽流感。目前高致病性H5N1病毒在野生和家禽中的地方性传播，以及由该病原体引起的一些严重的人类呼吸道疾病，刺激了开发潜在大流行性流感疫苗的必要性。讨论:在过去几年中，对如何预防H5N1流感进行了重大研究。减毒冷适应重组流感活疫苗(LAIV)被认为是最有希望用于大流行和大流行前疫苗的候选疫苗之一。LAIV已被证明是安全有效的;在提供更广泛的免疫反应方面，大流行性LAIV可能比灭活疫苗更有效。结论:本文综述了基于冷适应A/Leningrad/134/17/57 (H2N2)主供体病毒主干的抗H5N1亚型禽流感病毒的研制及其临床前和临床研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Open Microbiology Journal Immunology and Microbiology-Immunology and Microbiology (all)

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The Open Microbiology Journal is a peer-reviewed open access journal which publishes research articles, reviews/mini-reviews, case studies, guest edited thematic issues and short communications/letters covering theoretical and practical aspects of Microbial systematics, evolutionary microbiology, immunology, virology, parasitology , bacteriology, mycology, phycology, protozoology, microbial ecology, molecular biology, microbial physiology, biochemistry, microbial pathogenesis, host-microbe interaction, systems microbiology, synthetic microbiology, bioinformatics. The Open Microbiology Journal , a peer-reviewed journal, is an important and reliable source of current information on developments in the field. The emphasis will be on publishing quality papers rapidly and freely available to researchers worldwide.